Exceptions to Pharmaceutical Patents
The Agreement leaves considerable room for Member States to apply the standards of Article 29, which they may apply in a more stringent manner to promote innovation and competition. In addition, Member States are free to decide how far the information obligation on the applicant will extend, if the ...